Abstract | BACKGROUND: METHODS: AGC patients who had curative surgery and were classified as pathologically stage III were enrolled. At each 6-week treatment cycle, patients received weekly subcutaneous administration of the cocktail vaccine with 5 continuous injections and one break for the first 4 cycles and with bi-weekly injections for the following 4 cycles. S-1 (80 mg/m2) was administered orally for 4 weeks with 2-week rest for all 8 cycles. The primary endpoint was the safety of the combination therapy and the secondary was the relative dose intensity for S-1. RESULTS: Fourteen patients were enrolled. Six patients with HLA-A*2402 had received S-1 plus the cocktail vaccine as an adjuvant therapy and the remaining 8 had S-1 monotherapy for eight cycles. Five out of 6 patients subjected to the combination group completed the therapy and one patient discontinued because of Grade 3 injection-site reaction. No adverse events of grade 3 or higher were observed except injection-site reactions shown in 5 out of 6 patients who had vaccine therapy. The mean and median relative dose intensities for S-1 were 75.5% and 88% in the combination group and 67% and 80.5% in S-1. CONCLUSION: The vaccine therapy combined with S-1 was manageable and safe adjuvant therapy for stage III gastric cancer. Furthermore, the optimal relative dose intensity of S-1 was achieved in combination group, although the injection-site reaction should be considered.
|
Authors | Yoshiyuki Fujiwara, Keijiro Sugimura, Hiroshi Miyata, Takeshi Omori, Hiroyuki Nakano, Chie Mochizuki, Katsuji Shimizu, Hiroaki Saito, Keigo Ashida, Soichiro Honjyo, Yusuke Nakamura, Masahiko Yano |
Journal | Yonago acta medica
(Yonago Acta Med)
Vol. 60
Issue 2
Pg. 101-105
(06 2017)
ISSN: 0513-5710 [Print] Japan |
PMID | 28701892
(Publication Type: Journal Article)
|